Floatz logo

e6 tcr

Anal Carcinoma

National Cancer Institute (NCI)Cell therapyPhase 1/2Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
73/ 100

Competitive context

46 Active assets in the Anal Carcinoma cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Federation Francophone de Cancerologie Digestive
Phase 3BB
Carboplatin
Dustin Deming
Phase 3BB
Nivolumab
Instituto do Cancer do Estado de São Paulo
Phase 3BB
Irinotecan
University of Cincinnati
Phase 3BB
MITOMYCIN C
Federation Francophone de Cancerologie Digestive
Phase 3BB

View all 50 →

Same molecule, other indications

e6 tcr is also rated in:

oropharyngeal carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
vaginal cancerDormant
CCC
Indicative ·
50 / 100
View asset →
penile cancerDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →